tirzepatide cardiovascular outcomes outcomes. Forest plot comparing versus GLP‐1 tirzepatide cardiovascular outcome Comparison of
Description
Nat Med 27(8):14711476
This allows for convenient once-weekly dosing
Patients should seek medical advice if symptoms are severe or persistent
Top-line results of the Phase 2 trial demonstrated metopimazine led to a 40% reduction in the incidence of nausea and a 56% reduction in frequency of vomiting
This weekly schedule became the foundation for commercial semaglutide products and clinical trial protocols
